SOURCE: ViaDerma, Inc.

August 18, 2017 08:00 ET

ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan

Viaderma, Inc. announces Galaxy Solutions, Inc. as new sales representative for select Asia Pacific markets

LOS ANGELES, CA--(Marketwired - August 18, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today that it has appointed Galaxy Solutions, Inc. as its sales representative for its first aid topical antibiotic which will be sold under the brand name Vitastem in select markets of Asia Pacific, starting in Japan. The agreement includes sales and marketing responsibilities of the Vitastem brand and possible other brands that will be developed for specific market segments. Galaxy Solutions, Inc. will work to sell directly to larger customers and to distributors and will be the primary provider of service and support in the covered markets.

"With Galaxy Solutions as our sales representative, we will immediately have access to the professional segment of our target markets," said Dr. Chris Otiko, CEO of Viaderma, Inc. "Our goal is to continuously increase our revenues and improve our customers' experience in every aspect. Expanding our network of sales and support personnel and being in close proximity to where our customers are is a key initiative towards achieving that. With competitive pricing for retail sales through doctor's offices in Japan, the Company is conservatively estimating 2018 sales in Japan alone at approximately $12 million US dollars."

"Over the last 7 years Galaxy Solutions has established itself as a premier supplier of epidermal healing solutions, anti-aging solutions and beautification solutions. The relationship with Galaxy Solutions, Inc. will allow us to introduce our products to several markets, initially in Japan and then throughout Asia Pacific, immediately," said Otiko.

"Product testing has already begun and we are expecting to place an initial order in the next 30-45 days. I expect sales to be at around 10,000 units per month in the first 4-6 months and we hope to double that to 20,000 units per month in 2018 in Japan alone. The current testing is being done on sores resulting form side effects of cancer treatments and this will be our initial market, next we expect to introduce a product for acne," said Don Heath, President and CEO of Galaxy Solutions, Inc.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com.

About Galaxy Solutions, Inc.

Galaxy Solutions, Inc. is run by its CEO, Don Heath, a veteran in the area of product positioning and sales. After a successful career developing strategic global sales initiatives for fortune 100 companies in the 1980's, 90's and early 2000's, Don decided that he would move to Japan and set up his own Sales Representation company. Today, Don has developed deep relationships with retailers and distributors throughout Asia Pacific and has introduced many products to the Asia Pacific Market.

Forward-Looking Statements

Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact Information